Clinical Trials Logo

Portal Vein Tumor Thrombosis clinical trials

View clinical trials related to Portal Vein Tumor Thrombosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04104074 Recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Start date: November 25, 2019
Phase: Phase 1
Study type: Interventional

The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.

NCT ID: NCT03730675 Recruiting - Clinical trials for Hepatocellular Carcinoma

Irradiation Stent Placement Plus TACE for HCC and PVTT

Start date: November 10, 2018
Phase: N/A
Study type: Interventional

The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE compared to sorafenib plus TACE in patients with advanced HCC accompanied by portal vein tumor thrombosis. Patients will be randomized to receive either portal irradiation stent placement plus TACE(Arm A) or Sorafenib plus TACE (Arm B).

NCT ID: NCT02290977 Recruiting - Clinical trials for Hepatocellular Carcinoma

Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)

Start date: November 2014
Phase: Phase 2
Study type: Interventional

The presence of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months. In the HCC patients who combined with PVTT, Radiation therapy (RT) showed 50% of local control and about 10 months survival duration. Despite the standard treatment of the HCC combined with PVTT is sorafenib, but Korean Liver Cancer Study Group (KLCSG) recommend RT as an alternative option in those patients. Investigators previously reported the retrospective study that the scheduled interval Trans-catheter Arterial Chemo-embolization (TACE) followed by RT for HCC combined with PVTT and 60% of the patients showed objective response without significant elevation of complication. However, the prospective outcomes of TACE followed by RT for HCC are scantly reported. Based on those background, we start this prospective study to evaluate the clinical outcomes and adverse event in the RT after TACE in the unresectable HCC patients who combined with PVTT.